NanoViricides Inc. (NNVC)

[BonelessCat]

Let's look ate possible valuations for NNVC:

Currently completing animal studies and known to be entering pre-IND tox package:

Hiv-Cide for treatment of AIDS-- potential market $3 to $5 billion

Dengue-Cide treatment for Dengue and in particular DHF-- potential market over $1 billion

HSV-1 and HSV-2 treatment for genital Herpes-- potential market well over $1 billion

Once one indication is approved, the other 2 indications will be less than a year from market or revenue.

So, $1 billion divided by 200 million shares o/s worse case scenario leaves $5 earnings for each indication.

That sure looks like a share price over $2 to me.

If you disagree with the above you really, really don't know anything about NNVC, it's market potential, its technology, or the likelihood of approval.